Does the Australian drug development biotech sector create investor value? What are the impediments to value creation for biotech companies in Australia? Industry researcher and CEO of Race Oncology, Peter Molloy, will present answers to these questions at AusBiotech 2017. Based on public biotech company data from 2003 to 2016, Peter’s research represents the first long-term performance analysis of the drug development biotech sector in Australia, based on investor returns and value creation.
Set to play an instrumental role in advancing Australian innovation, Charlie Day is tasked with developing a strategy to build a robust and effective innovation system by 2030. Delivering a plenary presentation at AusBiotech 2017, Charlie, the Chief Executive Officer of Innovation and Science Australia (ISA), will provide an update on the Innovation, Science and Research (ISR) System and strategic plan development.
Read Charlie Day names his top challenges as CEO of Innovation and Science Australia from the Australian Financial Review.
How can supply chain development help create cures in the twenty-first century? In his plenary presentation, Tim Oldham will examine supply chains from a biotech perspective and discuss its implications for product development. Tim is the Chief Executive Officer of Cell Therapies, which is a recognised leader in manufacturing and distribution of cell-based therapies.
Read more about Cell Therapies.